Trio CRISPR/Cas9 KO Plasmid (h): sc-401231
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Trio CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Trio genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Trio CRISPR/Cas9 KO Plasmid (h) | sc-401231 | 20 µg | $397.00 |
Overview
TRIO encodes Trio, a large multidomain Rho guanine nucleotide exchange factor that activates Rac1 and RhoA family GTPases to coordinate actin cytoskeleton remodeling, membrane trafficking, and cell polarity. Trio integrates signaling from cell-surface receptors to downstream pathways governing neurite outgrowth, axon guidance, and synapse organization, with additional roles in cell migration and adhesion. Dysregulated TRIO signaling and variants affecting GEF activity have been linked to neurodevelopmental phenotypes and altered Rho GTPase network behavior in diverse cellular contexts, making it a useful node for studying cytoskeletal control and signal integration.
Trio CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TRIO gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TRIO together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TRIO open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Trio protein expression.
This CRISPR knockout system enables efficient generation of TRIO-deficient cell models for investigation of Trio signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TRIO exon(s) critical for Trio function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TRIO genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Trio CRISPR/Cas9 KO Plasmid (h) and Trio CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TRIO locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Trio HDR Plasmid (h) and Trio HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TRIO homology arms to support homology-directed repair at defined TRIO target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.